SKI‐G‐801, an AXL kinase inhibitor, blocks metastasis through inducing anti‐tumor immune responses and potentiates anti‐PD‐1 therapy in mouse cancer models
Clinical & Translational Immunology2021Vol. 11(1), pp. e1364–e1364
Citations Over Time
Chun‐Bong Synn, Sung Eun Kim, Hee Kyu Lee, Min Hwan Kim, Jae Hwan Kim, Ji Min Lee, Ha Ni Jo, Wongeun Lee, Dong Kwon Kim, Youngseon Byeon, Young Seob Kim, Mi Ran Yun, Chae‐Won Park, Jiyeon Yun, Sangbin Lim, Seong Gu Heo, Shuxiang Yang, Eun Ji Lee, Seul Lee, Hunmi Choi, You Won Lee, Jae Seok Cho, Do Hee Kim, Sung Ho Park, Jung Ho Kim, Yewon Choi, Sung Sook Lee, Beung‐Chul Ahn, Chang Gon Kim, Sun Min Lim, Min Hee Hong, Hye Ryun Kim, Kyoung‐Ho Pyo, Byoung Chul Cho
Abstract
SKI-G-801 significantly suppressed tumor metastasis and growth by enhancing anti-tumor immune responses. Our results suggest that SKI-G-801 has the potential to overcome anti-PD-1 therapy resistance and allow more patients to benefit from anti-PD-1 therapy.
Related Papers
- → Probiotics Mechanism of Action on Immune Cells and Beneficial Effects on Human Health(2023)724 cited
- → Immunometabolism in the tumor microenvironment and its related research progress(2022)28 cited
- → Immune System(2019)10 cited
- → The immune system(1996)8 cited
- Research Progress of Immune Cell Function in Patients with Recurrent Genital Herpes(2012)